Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing-Reference-Cited by-同舟云学术

Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing

Published:2018-06 Issue:6 Volume:40 Page:963-972
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

DiMasi Joseph A.,Smith Zachary,Getz Kenneth A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference8 articles.

1. Innovation in the pharmaceutical industry: new estimates of R&D costs;DiMasi;J Health Econ,2016

2. CMOS must embrace flexible manufacturing;Miller;Pharmaceutical Technology,2017

3. From CMO to CDMO: Opportunities for Specializing and Innovation;Jones;BioProcess International,2016

4. High-Potency APIs and Biologic Manufacturing Present Strong Growth Opportunities for Contract Manufacturing Organizations;Schöneborn;Frost & Sullivan,2016

5. Integrating drug discovery and development to improve efficiency and candidate success;Mirsaidi;Pharma’s Almanac,2016

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting calciumopathy for neuroprotection: focus on calcium channels Cav1, Orai1 and P2X7;Cell Calcium;2024-11

2. Assessing the net financial benefits of employing digital endpoints in clinical trials;Clinical and Translational Science;2024-07-28

3. Contract development and manufacturing organization selection: critical considerations that can make or break your cell and gene therapy development;Cytotherapy;2024-07

4. Assessing the Value of Integrated Evidence Approaches in Drug Development;2024-04-29

5. ASSESSING THE NET FINANCIAL BENEFITS OF EMPLOYING DIGITAL ENDPOINTS IN CLINICAL TRIALS;2024-03-09